Stammdaten
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Unternehmen & Branche
| Name | Vivos Therapeutics, Inc. |
|---|---|
| Ticker | VVOS |
| CIK | 0001716166 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,1 Mio. USD |
| Beta | 6,90 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 17,443,000 | -21,170,000 | -2.07 | 25,152,000 | -1,490,000 |
| 2025-09-30 | 10-Q | 6,783,000 | -5,400,000 | -0.49 | 25,644,000 | 2,532,000 |
| 2025-06-30 | 10-Q | 3,820,000 | -5,013,000 | -0.55 | 26,033,000 | 4,583,000 |
| 2025-03-31 | 10-Q | 3,016,000 | -3,864,000 | -0.45 | 11,282,000 | 4,407,000 |
| 2024-12-31 | 10-K | 15,031,000 | -11,136,000 | -2.22 | 15,284,000 | 7,954,000 |
| 2024-09-30 | 10-Q | 3,860,000 | -2,616,000 | -0.40 | 15,347,000 | 7,665,000 |
| 2024-06-30 | 10-Q | 4,054,000 | -1,930,000 | -0.60 | 15,842,000 | 6,347,000 |
| 2024-03-31 | 10-Q | 3,419,000 | -3,763,000 | -1.63 | 11,804,000 | 582,000 |
| 2023-12-31 | 10-K | 13,801,000 | -13,583,000 | -11.14 | 10,730,000 | 411,000 |
| 2023-09-30 | 10-Q | 3,301,000 | -2,093,000 | -1.75 | 10,317,000 | 46,000 |
| 2023-06-30 | 10-Q | 3,395,000 | -5,528,000 | -4.62 | 13,749,000 | 2,106,000 |
| 2023-03-31 | 10-Q | 3,857,000 | -1,703,000 | -1.72 | 17,100,000 | 6,993,000 |
| 2022-12-31 | 10-K | 16,024,000 | -23,845,000 | -25.90 | 13,720,000 | 4,801,000 |
| 2022-09-30 | 10-Q | 4,246,000 | -5,434,000 | -6.40 | 18,400,000 | 9,855,000 |
| 2022-06-30 | 10-Q | 4,184,000 | -6,992,000 | -0.33 | 24,375,000 | 14,839,000 |
| 2022-03-31 | 10-Q | 3,644,000 | -5,331,000 | -0.25 | 29,556,000 | 21,039,000 |
| 2021-12-31 | 10-K | 16,885,000 | -20,288,000 | 33,689,000 | 25,539,000 | |
| 2021-09-30 | 10-Q | 4,546,000 | -5,453,000 | 41,024,206 | 32,469,000 | |
| 2021-06-30 | 10-Q | 4,497,000 | -4,043,000 | 46,156,308 | 36,479,000 | |
| 2021-03-31 | 10-Q | 3,448,000 | -3,399,000 | 21,953,902 | 14,340,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Skaff Michael C | 10% Owner | Open Market Purchase | 308,848 | 1.34 | 413,856.32 | +45,6% | |
| 2026-03-31 | Skaff Michael C | 10% Owner | Open Market Purchase | 1,044,777 | 1.34 | 1,400,001.18 | +154,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.